

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Jiang	Art Unit: 1627
Application No.: 13/597,884	Examiner: Kara R. McMillian
Filed: August 29, 2012	Docket No.: FKA01_007_US
Title: Levothyroxine Formulations	

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This communication responds to the Office Action mailed on March 6, 2014. Applicants respectfully request that Examiner McMillian reconsider the rejections in view of the following amendments and remarks. This paper is believed to be timely filed.

Amendments to the Claims are reflected in the listing of claims beginning on page 2.

Remarks begin on page 7.

Declaration pursuant to 37 CFR § 1.132 of Leonard J. Chyall is included with the response.

IN THE CLAIMS:

In accord with Rule § 1.121, a complete claim listing is presented below. A status identifier (Original), (Previously Presented), or (Currently Amended) precedes each claim. The changes in amended claims are shown by strikethrough or double brackets for deleted material, and by underlining for added material.

1.-10. (Canceled)

11. (Currently Amended) A composition, comprising:
from 100 to 200 micrograms of levothyroxine sodium
a phosphate buffer, and
mannitol;
where the mass ratio of mannitol to levothyroxine sodium is ~~at most 40:1~~ from 1:1
to 40:1, and
the composition is a lyophilized solid.
12. (Currently Amended) The composition of claim 11, where the amount of levothyroxine sodium is about 100 micrograms and the mass ratio of mannitol to levothyroxine sodium is about 30:1.
13. (Currently Amended) The composition of ~~claim 12~~ claim 11, where the amount of levothyroxine sodium is about 200 micrograms and the mass ratio of mannitol to levothyroxine sodium is ~~at most 30:1~~ about 15:1.
14. (Currently Amended) The composition of ~~claim 13~~, ~~further comprising a~~ claim 12, where the phosphate buffer is dibasic sodium phosphate in an amount from 400 to 600 micrograms.
15. (Original) The composition of claim 14, where the composition is formed by forming a liquid mixture by combining

- the levothyroxine sodium,
the mannitol,
dibasic sodium phosphate, and
a solvent comprising water; and
lyophilizing the liquid mixture.
16. (Currently Amended) The composition of ~~claim 15, where the amount of dibasic sodium phosphate in the liquid mixture is from 400 to 600 micrograms~~ claim 11, where when the composition is stored at 25 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 12 months.
17. (Currently Amended) The composition of claim 11, where ~~the amount of levothyroxine sodium is about 200 micrograms~~ when the composition is stored at 40 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 3 months.
18. (Currently Amended) The composition of ~~claim 17, where the mass ratio of mannitol to levothyroxine sodium is at most 15:1~~ claim 14, when the composition is stored at 25 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 12 months.
19. (Currently Amended) The composition of ~~claim 18, further comprising a~~ claim 13, where the phosphate buffer is dibasic sodium phosphate in an amount from 400 to 600 micrograms.
20. (Original) The composition of claim 19, where the composition is formed by forming a liquid mixture by combining
the levothyroxine sodium,
the mannitol,
dibasic sodium phosphate, and
a solvent comprising water; and

- lyophilizing the liquid mixture.
21. (Currently Amended) The composition of ~~claim 20, where the amount of dibasic sodium phosphate in the liquid mixture is from 400 to 600 micrograms~~ claim 14, where when the composition is stored at 40 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 3 months.
22. (Currently Amended) The composition of ~~claim 14~~ claim 19, where when the composition is stored at 25 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 12 months.
23. (Currently Amended) The composition of ~~claim 14~~ claim 19, where when the composition is stored at 40 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 3 months.
24. (Currently Amended) A composition, comprising:
about 500 micrograms of levothyroxine sodium,
a phosphate buffer, and
mannitol;
where the mass ratio of mannitol to levothyroxine sodium is ~~at most 10:1~~ from 2:1 to 10:1, and the composition is a lyophilized solid.
25. (Currently Amended) The composition of claim 24, where the mass ratio of mannitol to levothyroxine sodium is ~~at most~~ about 6:1.
26. (Currently Amended) The composition of claim 25, ~~further comprising a~~ where the phosphate buffer is dibasic sodium phosphate in an amount from 400 to 600 micrograms.
27. (Original) The composition of claim 26, where the composition is formed by forming a liquid mixture by combining
the levothyroxine sodium,

the mannitol,
dibasic sodium phosphate, and
a solvent comprising water; and
lyophilizing the liquid mixture.

28. (Currently Amended) The composition of ~~claim 27~~, where the amount of dibasic sodium phosphate in the liquid mixture is from 400 to 600 micrograms dibasic sodium phosphate claim 24, where when the composition is stored at 25 °C, at most 0.15% of the levothyroxine sodium is converted to liothyronine over a period of 12 months.

29. (Currently Amended) The composition of ~~claim 24~~ claim 26, where when the composition is stored at 25 °C, at most 0.15% of the levothyroxine sodium is converted to liothyronine over a period of 12 months.

30. (Currently Amended) The composition of ~~claim 24~~ claim 26, where when the composition is stored at 40 °C, at most 0.15% of the levothyroxine sodium is converted to liothyronine over a period of 3 months.

31. (New) The composition of claim 24, where when the composition is stored at 40 °C, at most 0.15% of the levothyroxine sodium is converted to liothyronine over a period of 3 months.

32. (New) The composition of claim 11, where the mass ratio of mannitol to levothyroxine sodium is from 5:1 to 35:1.

33. (New) The composition of claim 32, where when the composition is stored at 25 °C, at most 0.20% of the levothyroxine sodium is converted to liothyronine over a period of 12 months.

34. (New) The composition of claim 32, where the phosphate buffer is dibasic sodium phosphate in an amount from 400 to 600 micrograms.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.